GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Future Policy Benefits

RGBP (Regen BioPharma) Future Policy Benefits


View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.


Regen BioPharma Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.